Literature DB >> 29363835

Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.

Xiao Feng Hu1, Rui Zhan2, Shanhu Xu3, Junjun Wang3, Jiong Wu3, Xiaoli Liu3, Yaguo Li3, Linhui Chen3.   

Abstract

BACKGROUND: There is evidence suggesting that growth differentiation factor 15 (GDF-15) appears to be associated with stroke in patients with atrial fibrillation (AF). AF-related thromboembolic stroke is predominantly attributed to the thrombus from the left atrium (LA) or left atrial appendage (LAA). HYPOTHESIS: GDF-15 is related to LA/LAA thrombus in nonvalvular AF (NVAF) patients.
METHODS: A total of 894 patients with NVAF without anticoagulation therapy were included in this study. All patients routinely underwent transesophageal echocardiography for detection of LA/LAA thrombus. GDF-15 was measured by enzyme-linked immunosorbent assay. Logistic regression models were used to test for association.
RESULTS: LA/LAA thrombus was detected by transesophageal echocardiography in 69 (7.72%) patients with AF. The GDF-15 levels in the patients with LA/LAA thrombus were significantly higher than those without LA/LAA thrombus (log10 GDF-15: 2.989 ± 0.023 ng/L vs 2.831 ± 0.007 ng/L; P < 0.001). Logistic regression analysis showed that GDF-15 was an independent risk factor for LA/LAA thrombus (odds ratio [per quarter]: 1.799, 95% confidence interval: 1.381-2.344, P < 0.001) after adjusting for potential clinical risk factors. The optimal cutoff point for GDF-15 predicting LA/LAA thrombus was 809.9 ng/L (sensitivity, 75.3%; specificity, 61.5%), determined by ROC curve. The area under the curve was 0.709 (95% confidence interval: 0.644-0.770, P < 0.001).
CONCLUSIONS: Elevated GDF-15 indicated a significantly increased risk for LA/LAA thrombus in NVAF patients. Thus, GDF-15 might be a potentially useful adjunct in discriminating LA/LAA thrombus in NVAF patients.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Atrial Fibrillation; Biomarkers; Growth Differentiation Factor 15; Left Atrial/Left Atrial Appendage Thrombus

Mesh:

Substances:

Year:  2018        PMID: 29363835      PMCID: PMC6489975          DOI: 10.1002/clc.22844

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  32 in total

1.  Growth-differentiation factor-15 in cardiovascular disease: from bench to bedside, and back.

Authors:  Kai C Wollert
Journal:  Basic Res Cardiol       Date:  2007-06-05       Impact factor: 17.165

2.  Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury.

Authors:  E C Hsiao; L G Koniaris; T Zimmers-Koniaris; S M Sebald; T V Huynh; S J Lee
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

3.  Expression of a TGF-beta superfamily protein, macrophage inhibitory cytokine-1, in the yeast Pichia pastoris.

Authors:  W D Fairlie; H Zhang; P K Brown; P K Russell; A R Bauskin; S N Breit
Journal:  Gene       Date:  2000-08-22       Impact factor: 3.688

Review 4.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

5.  Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation.

Authors:  Seiji Habara; Keigo Dote; Masaya Kato; Shota Sasaki; Kenji Goto; Hiroaki Takemoto; Daiji Hasegawa; Osamu Matsuda
Journal:  Eur Heart J       Date:  2007-08-22       Impact factor: 29.983

6.  Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.

Authors:  Tibor Kempf; Stephan von Haehling; Timo Peter; Tim Allhoff; Mariantonietta Cicoira; Wolfram Doehner; Piotr Ponikowski; Gerasimos S Filippatos; Piotr Rozentryt; Helmut Drexler; Stefan D Anker; Kai C Wollert
Journal:  J Am Coll Cardiol       Date:  2007-08-24       Impact factor: 24.094

7.  Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.

Authors:  Kai C Wollert; Tibor Kempf; Timo Peter; Sylvia Olofsson; Stefan James; Nina Johnston; Bertil Lindahl; Rüdiger Horn-Wichmann; Georg Brabant; Maarten L Simoons; Paul W Armstrong; Robert M Califf; Helmut Drexler; Lars Wallentin
Journal:  Circulation       Date:  2007-02-05       Impact factor: 29.690

8.  Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis.

Authors:  Yoichi Nakamura; Kazufumi Nakamura; Kengo Fukushima-Kusano; Keiko Ohta; Hiromi Matsubara; Tsutomu Hamuro; Chikao Yutani; Tohru Ohe
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

9.  Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions.

Authors:  Daniel Schlittenhardt; Andreas Schober; Jens Strelau; Gabriel A Bonaterra; Walther Schmiedt; Klaus Unsicker; Jürgen Metz; Ralf Kinscherf
Journal:  Cell Tissue Res       Date:  2004-10-01       Impact factor: 5.249

10.  Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study.

Authors:  David A Brown; Samuel N Breit; Julie Buring; W Douglas Fairlie; Asne R Bauskin; Tao Liu; Paul M Ridker
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

View more
  9 in total

Review 1.  GDF-15 as a Biomarker in Cardiovascular Disease.

Authors:  Bruna Miers May; Mauricio Pimentel; Leandro Ioschpe Zimerman; Luis Eduardo Rohde
Journal:  Arq Bras Cardiol       Date:  2021-03       Impact factor: 2.000

2.  Growth differentiation factor-15 and the risk of cardiovascular diseases and all-cause mortality: A meta-analysis of prospective studies.

Authors:  Shanhui Xie; Liping Lu; Liwei Liu
Journal:  Clin Cardiol       Date:  2019-03-26       Impact factor: 2.882

3.  Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.

Authors:  Paweł T Matusik; Barbara Małecka; Jacek Lelakowski; Anetta Undas
Journal:  Clin Res Cardiol       Date:  2019-07-06       Impact factor: 5.460

Review 4.  Atrial Myopathy.

Authors:  Mark J Shen; Rishi Arora; José Jalife
Journal:  JACC Basic Transl Sci       Date:  2019-09-23

Review 5.  Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.

Authors:  Mario Piergiulio Pezzo; Antonella Tufano; Massimo Franchini
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

6.  Laboratory medicine in pandemic of COVID-19.

Authors:  Leida Tandara; Petra Filipi; Daniela Supe Domic; Branka Kresic; Ivo Ivcic; Sanda Stojanovic Stipic; Zana Rubic; Marijan Tandara
Journal:  Biochem Med (Zagreb)       Date:  2022-04-15       Impact factor: 2.313

Review 7.  A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.

Authors:  Luxiang Shang; Ling Zhang; Yankai Guo; Huaxin Sun; Xiaoxue Zhang; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Front Cardiovasc Med       Date:  2021-07-01

8.  Plasma growth differentiation factor-15 in patients with "lone" atrial fibrillation.

Authors:  Na Li; Qian Feng; Fangfang Yu; Jian Zhou; Xueyuan Guo
Journal:  J Clin Lab Anal       Date:  2022-03-25       Impact factor: 3.124

9.  Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation.

Authors:  Zefeng Wang; Liting Cheng; Junmeng Zhang; Zhuo Liang; Ruiqing Dong; Fei Hang; Xinlu Wang; Ziyu Wang; Yongquan Wu; Jie Du
Journal:  Med Sci Monit       Date:  2020-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.